[1] |
Yang JD,Hainaut P,Gores GJ,et al. A global view of hepatocellular carcinoma: trends,risk,prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
|
[2] |
阿力木江·买合木提,冷超,徐磊,等. APRI在肝细胞癌淋巴结转移术后患者预后中的价值[J/OL]. 中华肝脏外科手术学电子杂志,2020,9(6):529-532.
|
[3] |
Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
|
[4] |
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024 年版)[J/OL]. 中华肝脏外科手术学电子杂志,2024,13(4):407-449.
|
[5] |
Duran R,Sharma K,Dreher MR,et al. A novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study[J]. Theranostics,2016,6(1):28-39.
|
[6] |
Artinyan A,Nelson R,Soriano P,et al. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver[J]. HPB,2008,10(6):396-404.
|
[7] |
Lu LH,Wei W,Li SH,et al. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE[J]. Aging,2021,13(4):5358-5368.
|
[8] |
Cucchetti A,Cappelli A,Golfieri R. Reply to external validation of an individual prognostic calculator after trans-arterial chemoembolization for hepatocellular carcinoma[J]. Liver Int,2016,36(8):1232.
|
[9] |
Minici R,Siciliano MA,Ammendola M,et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR),lymphocyte-to-monocyte ratio (LMR),platelet-to-lymphocyte ratio (PLR) and lymphocyteto-C reactive protein ratio (LCR) in Patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: the unexplored corner linking tumor microenvironment,biomarkers and interventional radiology[J]. Cancers,2022,15(1):257.
|
[10] |
Calderaro J,Petitprez F,Becht E,et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma[J]. J Hepatol,2019,70(1):58-65.
|
[11] |
石凤翔,李晓雯,柳青,等. 肝切除术与肝动脉化疗栓塞术治疗伴大血管侵犯肝细胞癌成本效果分析[J]. 中华肿瘤防治杂志,2019,26(9):603-608.
|
[12] |
Komorowski AL,Hsu CC,Julka KD,et al. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients[J]. Neoplasma,2018,65(3):455-460.
|
[13] |
Golfieri R,Cappelli A,Cucchetti A,et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm) hepatocellular carcinomas[J]. Hepatology,2011,53(5):1580-1589.
|
[14] |
中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学会肝癌学组,等. 原发性肝癌规范化病理诊断方案专家共识[J]. 临床肝胆病杂志,2011,27(4):343-345.
|
[15] |
刘华江,邓堂,颜运智,等. 术前NLR联合AFP对肝细胞癌患者TACE术后预后的预测价值[J]. 中国临床医学影像杂志,2019,30(10):716-720,747.
|
[16] |
蔡越飞,王凯,冼重杨,等. AFP和MKP-1对无法切除的肝细胞癌患者经TACE术治疗的预后预测价值[J]. 国际消化病杂志,2021,41(6):427-432.
|
[17] |
罗清兰,邓宇伟,曾涛. 原发性肝癌术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和甲胎蛋白对预后的评估分析[J]. 当代医学,2022,28(19):18-21.
|
[18] |
Mehrpour M,Afrakhte M,Shojaei SF,et al. Factors predicting the outcome of intravenous thrombolysis in stroke patients before rt-PA administration[J]. Caspian J Intern Med,2019,10(4):424-430.
|
[19] |
Vaclavik D,Vilionskis A,Jatuzis D,et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis[J]. Acta Neurol Scand,2018,137(3):347-355.
|
[20] |
鲍乐,李鹏飞,王友彬,等. 晚期肝癌TACE术后再次复发的风险因素分析[J]. 中国现代医生,2021,59(34):1-3,7.
|
[21] |
赵露,姜文雯,张馨,等. 原发性肝癌患者肝动脉化疗栓塞术前行肝硬化CT分级对术后1年中位生存期和生存率的影响[J]. 肝脏,2018,23(12):1117-1119.
|
[22] |
Wang J,Chen Z,Wang L,et al. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection[J]. Sci Rep,2022,12(1):8670.
|
[23] |
Wang D,Bai N,Hu X,et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J].PeerJ,2019,7:e7132.
|
[24] |
Schrader J,Iredale JP. The inflammatory microenvironment of HCC -the plot becomes complex[J]. J Hepatol,2011,54(5):853-855.
|
[25] |
Sanghera C,Teh JJ,Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma[J]. Liver Int,2019,39(11):2008-2023.
|
[26] |
张迪铭,葛海蓉. C反应蛋白和降钙素原检测在恶性肿瘤患者感染性疾病中的应用[J]. 中国肿瘤临床与康复,2022,29(1):73-75.
|
[27] |
杜成荣,丁德权,曹齐生,等. 老年原发性肝癌患者TACE术后发生肝功能代偿不全的影响因素[J]. 中国老年学杂志,2022,42(11):2648-2651.
|
[28] |
Meischl T,Rasoul-Rockenschaub S,Györi G,et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation[J]. PLoS One,2019,14(5):e0216677.
|
[29] |
Lokken RP,Kerlan RK,Chung YC,et al. Hepatic toxicity after selective chemoembolization is associated with decreased survival among patients with hepatocellular carcinoma[J]. AJR Am J Roentgenol,2021,216(5):1283-1290.
|
[30] |
Zhao X,Dou J,Cao J,et al. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database[J]. Oncol Rep,2020,43(6):1771-1784.
|
[31] |
Loosen SH,Schulze-Hagen M,Leyh C,et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies[J]. Int J Mol Sci,2018,19(6):1766.
|